For the Inventor, By the Inventor

Enter inventor name

Traunstein, Germany

Juergen Michael Schanzer

USPTO Granted Patents = 17 (Patent Applications = 19)

CIPO Patents = 4 (Patent Applications = 4)

EPO Patents = 12 (Patent Applications = 17)

Average Co-Inventor Count = 7.3

ph-index = 8

Forward Citations = 271(Granted Patents)

Location History:

Muensing, DE (2012 - 2017)
Munich, DE (2017 - 2023)
Traunstein, DE (2014 - 2024)

Company Filing History:

14 out of 4,942

Hoffmann-la Roche Inc.

Roche Glycart Ag

Years Active: 2012-2024

where 'Filed Patents' based on already Granted Patents

17 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11993642 - Trivalent, bispecific antibodies (2024-05-28),

2. 11787873 - Bispecific HER2 antibodies and methods of use (2023-10-17),

3. 11673945 - Bispecific antigen binding proteins (2023-06-13),

4. 11242390 - Protease-activated T cell bispecific molecules (2022-02-08),

5. 10640555 - Bispecific antigen binding proteins (2020-05-05),

6. 10584178 - Bispecific HER2 antibodies and methods of use (2020-03-10),

7. 10106600 - Bispecific antibodies (2018-10-23),

8. 9890204 - Trivalent, bispecific antibodies (2018-02-13),

9. 9879095 - Bispecific antibodies comprising a disulfide stabilized-Fv fragment (2018-01-30),

10. 9708396 - Bispecific anti-VEGF/anti-ANG-2 antibodies (2017-07-18),

11. 9676845 - Bispecific antigen binding proteins (2017-06-13),

12. 9650442 - Bispecific anti-EGFR/anti IGF-1R antibodies (2017-05-16),

13. 9382323 - Multispecific antibodies comprising full length antibodies and single chain fab fragments (2016-07-05),

14. 8796424 - Tri- or tetraspecific antibodies (2014-08-05),

15. 8703132 - Bispecific, tetravalent antigen binding proteins (2014-04-22),

Title: Juergen Michael Schanzer: Innovator in Antibody Development

Introduction

Juergen Michael Schanzer is a prominent inventor based in Traunstein, Germany, known for his significant contributions to the field of biopharmaceuticals. With a total of 17 patents to his name, Schanzer has made remarkable advancements in the development of antibodies.

Latest Patents

Among his latest patents are innovations related to trivalent, bispecific antibodies. The present invention pertains to trivalent, bispecific antibodies, methods for their production, pharmaceutical compositions containing these antibodies, and their various uses. Another notable patent involves bispecific HER2 antibodies and methods of use, which includes novel HER2 antibody variants, production methods, pharmaceutical compositions, and their applications.

Career Highlights

Schanzer has had a distinguished career, working with leading companies in the pharmaceutical industry. He has been associated with Hoffmann-La Roche Inc. and Roche Glycart AG, where he has contributed to groundbreaking research and development in antibody technology.

Collaborations

Throughout his career, Schanzer has collaborated with esteemed colleagues, including Christian Klein and Wolfgang Schaefer, further enhancing the impact of his work in the field.

Conclusion

Juergen Michael Schanzer's innovative work in antibody development has positioned him as a key figure in biopharmaceutical research. His contributions continue to influence the industry and pave the way for future advancements in medical treatments.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…